The binding site of IL-6 called gp130 was decreased and occupied by TRAFs which were upregulated by butyrate, leading to inhibition of the JAK2/STAT3 pathway beneficial for CRC (37). This evidence concerns the gene STAT3 and colorectal carcinoma.